Erratum

The November 1, 2018, article by Cruz et al entitled “Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy” (J Clin Oncol [10.1200/JCO.2018.78.6558](https://doi.org/10.1200/JCO.2018.78.6558)) was published with errors.

In Figure 1, the 6th box from the top on the left reads: Futility analysis: If fewer than four of 20 patients with response, continue recruitment to at least 53 patients Responses in the first 20 patients (n = 8) Recruitment Continued

This should have read: Futility analysis: If fewer than four of 20 patients with response **in arm A, stop** recruitment, **otherwise continue until** at least 53 **evaluable** patients Responses in the first 20 patients (n = 8) Recruitment Continued

In Figure 1, the 6th box from the top on the right reads: Futility analysis: If fewer than three of 30 patients with response, continue recruitment to at least 64 patients Responses in the first 30 patients (n = 2) Recruitment was closed

This should have read: Futility analysis: If fewer than three of 30 patients with response, **stop** recruitment, **otherwise continue until** at least 64 **evaluable** patients Responses in the first 30 patients (n = 2) Recruitment was closed

This has been corrected as of October 18, 2018. The authors apologize for the errors.

DOI: <https://doi.org/10.1200/JCO.18.01630>; published November 20, 2018